Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category, but picked up its first approval in the rare tumour Merkel cell carcinoma last ... in the control arm to cross over to ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

The following is a summary of “Improved survival at the population level for patients with advanced Merkel cell carcinoma ...

For example, a 5/1 ARM will have the same rate for the first five years, then can adjust each year after that—meaning the rate might go up or down, based on the market. An ARM isn’t for everyone.

Looking for a new Windows laptop with an Arm-based processor? We've got you covered with our in-depth roundup of the best on the market! When you purchase through links on our site, we may earn an ...

In this article, we are going to take a look at where ARM Holdings plc (NASDAQ:ARM) stands against the other UK growth stocks. The start of this year has marked interesting developments for the UK ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

2025 — Scientists have developed an innovative solar-powered method to transform sewage sludge -- a by-product of wastewater treatment -- into green hydrogen for clean energy and single-cell ...